Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2008 Oct;118(10):3260-3. doi: 10.1172/JCI37099.

Paradox of B cell-targeted therapies.

Author information

1
Laboratory of Lymphocyte Differentiation, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan. kurosaki@rcai.riken.jp

Abstract

The use of antibodies against the human B cell surface protein CD20 represents the most advanced therapeutic approach among the B cell-depleting armamentarium for the treatment of autoimmune disorders. However, recent evidence indicates that B cells can also be essential for suppressing unwanted autoaggressive T cell responses, and therefore, a more careful evaluation of which types of autoimmune disorders this therapy should be utilized for, and at which phases of disease this therapy should be applied, is necessary. In this issue of the JCI, Matsushita et al. report that the timing of this therapy is critical for the management of EAE, a mouse model of human MS (see the related article beginning on page 3420). The results suggest the existence of two opposite actions executed by B cells during the course of autoimmune pathology; CD1dhiCD5+ regulatory B cells suppress EAE induction, whereas B cells are required for the expansion of autoantigen-specific T cells during disease progression. Given the existence of such regulatory B cells in humans, these findings not only resolve previously unexplained contradictions with respect to the outcome of B cell-depleting therapy but also provide insight into the best regimen for this treatment approach.

PMID:
18802484
PMCID:
PMC2542854
DOI:
10.1172/JCI37099
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center